The next step in regenerative medicine for osteoarthritis: Spscs and a new regulatory pathway Osteoarthritis (OA) remains one of the leading causes of disability worldwide, burdening health systems and diminishing quality of life for millions. Over the last decade, regenerative medicine has advanced rapidly – from stromal vascular fraction (SVF) and platelet-rich fibrin (PRF) to cell-free therapies such as amniotic-derived exosomes. Our previous work has contributed to this evolution: first through SVF–PRF combination therapy showing sustained clinical improvements, and later through a large real-world evaluation of exosomes used both locally and systemically. Together, these studies strengthen the case for minimally invasive, biologically active therapies as an emerging pillar in OA care.
Torbjörn Ogéus (Fri,) studied this question.